<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928679</url>
  </required_header>
  <id_info>
    <org_study_id>137.05</org_study_id>
    <nct_id>NCT02928679</nct_id>
  </id_info>
  <brief_title>Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance</brief_title>
  <acronym>IM-LOSEIT-II</acronym>
  <official_title>Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis Following Liraglutide Treatment, Investigating the Impact on Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Gudbergsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parker Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a substudy to a randomised trial investigating the effect of liraglutide on body
      weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864). In
      the parent trial, patients will be subjected to an 8-week diet intervention phase including a
      low-calorie diet and dietetic counseling, after which patients will be randomised to receive
      either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on
      re-introducing regular foods and a focus on continued motivation to engage in a healthy
      lifestyle.

      This substudy aims to investigate the impact of, and subsequent change of, joint
      inflammation, articular cartilage composition, overall knee morphology, and clinical
      symptoms, in obese patients with knee osteoarthritis following a randomisation to Liraglutide
      3 mg or Liraglutide 3 mg placebo treatment between weeks 0-52.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the degree of inflammation in the knee-joint (DCE-MRI)</measure>
    <time_frame>Week 0 to 52</time_frame>
    <description>Change will be assessed via a dynamic contrast enhanced MRI evaluation of corpus hoffa (Ballegaard C et al. and Riis RG et al.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the degree of inflammation in the knee-joint (CE-MRI)</measure>
    <time_frame>Week 0 to 52</time_frame>
    <description>Change will be assessed via a static contrast enhanced MRI evaluation of the level of synovitis in the knee-joint (11 sites scored 0-2, ad modum Guermazi et al.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the degree of inflammation in the knee-joint (MRI)</measure>
    <time_frame>Week 0 to 52</time_frame>
    <description>Change will be assessed via a conventional MRI evaluation of the level of synovitis and effusion (combined) in the knee-joint (MOAKS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cartilage composition</measure>
    <time_frame>Week 0 to 52</time_frame>
    <description>Change will be assessed via T2-maps of cartilage in the weight-bearing parts of the knee-joint (ROI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone marrow lesions</measure>
    <time_frame>Week 0 to 52</time_frame>
    <description>Change will be assessed via the MRI knee scoring system MOAKS; BML sum-score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Liraglutide 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.
Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 3 mg placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.
Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide 3 mg (Saxenda)</intervention_name>
    <arm_group_label>Liraglutide 3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide 3 mg placebo</intervention_name>
    <arm_group_label>Liraglutide 3 mg placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Same as parent trial (NCT02905864)

        Further Exclusion Criteria:

          -  Same as parent trial (NCT02905864)

          -  Usual exclusion criteria for MRI (i.e. pacemakers etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Parker Institute and Department of Radiology at Bispebjerg and Frederiksberg Hospital</name>
      <address>
        <city>Frederiksberg</city>
        <state>Capital Region</state>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikael Boesen, MD, PhD</last_name>
      <phone>+45 38 16 46 54</phone>
      <email>mikael.ploug.boesen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>henrik r gudbergsen, MD, PhD</last_name>
      <phone>+45 29 84 28 88</phone>
      <email>henrik.rindel.gudbergsen.01@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>November 11, 2016</last_update_submitted>
  <last_update_submitted_qc>November 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Parker Research Institute</investigator_affiliation>
    <investigator_full_name>Henrik Gudbergsen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Dynamic contrast enhanced MRI</keyword>
  <keyword>Liraglutide 3 mg</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>Obesity</keyword>
  <keyword>Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

